1. Home
  2. INTS vs PMAX Comparison

INTS vs PMAX Comparison

Compare INTS & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • PMAX
  • Stock Information
  • Founded
  • INTS 2012
  • PMAX 2019
  • Country
  • INTS United States
  • PMAX Hong Kong
  • Employees
  • INTS N/A
  • PMAX N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • PMAX
  • Sector
  • INTS Health Care
  • PMAX
  • Exchange
  • INTS Nasdaq
  • PMAX Nasdaq
  • Market Cap
  • INTS 33.4M
  • PMAX 32.0M
  • IPO Year
  • INTS 2023
  • PMAX 2024
  • Fundamental
  • Price
  • INTS $2.20
  • PMAX $0.44
  • Analyst Decision
  • INTS Strong Buy
  • PMAX
  • Analyst Count
  • INTS 3
  • PMAX 0
  • Target Price
  • INTS $8.50
  • PMAX N/A
  • AVG Volume (30 Days)
  • INTS 40.1K
  • PMAX 4.2M
  • Earning Date
  • INTS 03-13-2025
  • PMAX 02-14-2025
  • Dividend Yield
  • INTS N/A
  • PMAX N/A
  • EPS Growth
  • INTS N/A
  • PMAX N/A
  • EPS
  • INTS N/A
  • PMAX 0.04
  • Revenue
  • INTS N/A
  • PMAX $5,970,263.00
  • Revenue This Year
  • INTS N/A
  • PMAX N/A
  • Revenue Next Year
  • INTS N/A
  • PMAX N/A
  • P/E Ratio
  • INTS N/A
  • PMAX $10.26
  • Revenue Growth
  • INTS N/A
  • PMAX 30.05
  • 52 Week Low
  • INTS $1.50
  • PMAX $0.34
  • 52 Week High
  • INTS $5.94
  • PMAX $4.70
  • Technical
  • Relative Strength Index (RSI)
  • INTS 54.20
  • PMAX N/A
  • Support Level
  • INTS $2.00
  • PMAX N/A
  • Resistance Level
  • INTS $2.37
  • PMAX N/A
  • Average True Range (ATR)
  • INTS 0.31
  • PMAX 0.00
  • MACD
  • INTS -0.00
  • PMAX 0.00
  • Stochastic Oscillator
  • INTS 48.24
  • PMAX 0.00

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

About PMAX Powell Max Limited Class A Ordinary Shares

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. Key revenue is derived from Hong Kong.

Share on Social Networks: